Search | Clinical Trials Finder

Conditions: Alopecia, Alopecia, Androgenetic, Baldness
Interventions: Bimatoprost Solution 1, Bimatoprost Solution 2, Bimatoprost Vehicle; Drug
Lead sponsor: Allergan; Industry
Eligibility: 18 Years to 49 Years · Male only
Enrollment: 244 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 1
States / cities: Fridley, Minnesota

Conditions: Glaucoma, Open-Angle Glaucoma, Ocular Hypertension, Glaucoma Suspect
Interventions: Durysta, Bimatoprost Intracameral Implant 10 µg; Drug
Lead sponsor: University of Miami; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Ocular Hypertension
Interventions: bimatoprost; Drug
Lead sponsor: Allergan; Industry
Eligibility: 18 Years and older
Enrollment: 561 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2007
U.S. locations: 1
States / cities: Newport Beach, California

Conditions: Open-angle Glaucoma, Ocular Hypertension
Interventions: Bimatoprost Ophthalmic Solution, 0.01%, LUMIGAN® (bimatoprost ophthalmic solution) 0.01%; Drug
Lead sponsor: Amneal Pharmaceuticals, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 240 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 4
States / cities: Bakersfield, California • Newport Beach, California • Morrow, Georgia + 1 more

Conditions: Migraine Disorders, Headache Disorders
Interventions: Bimatoprost Topical Solution, Control; Drug
Lead sponsor: Manistee Partners; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 2
States / cities: Cincinnati, Ohio • Warwick, Rhode Island

Conditions: Glaucoma, Open-Angle, Ocular Hypertension
Interventions: AGN-210669, bimatoprost, bimatoprost vehicle; Drug
Lead sponsor: Allergan; Industry
Eligibility: 18 Years and older
Enrollment: 125 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Primary Open-Angle Glaucoma, Ocular Hypertension
Interventions: Bimatoprost; Drug
Lead sponsor: ForSight Vision5, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 10
States / cities: Artesia, California • La Jolla, California • Newport Beach, California + 7 more

Conditions: Madarosis, Hypotrichosis
Interventions: Bimatoprost eyelash gel; Drug
Lead sponsor: Duke University; Other
Eligibility: 18 Years to 80 Years · Female only
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Glaucoma
Interventions: Bimatoprost 0.03%, Travoprost 0.004%; Drug
Lead sponsor: Innovative Medical; Industry
Eligibility: 18 Years and older
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Glaucoma
Interventions: bimatoprost ophthalmic solution formulation A, timolol ophthalmic solution, bimatoprost vehicle; Drug
Lead sponsor: Allergan; Industry
Eligibility: 2 Months to 17 Years
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 1
States / cities: Louisville, Kentucky

Conditions: Cataract, Glaucoma, Ocular Hypertension
Interventions: Bimatoprost Implant System, SpyGlass IOL, Timolol Maleate Ophthalmic Solution, 0.5%, Commercial IOL; Drug · Device
Lead sponsor: SpyGlass Pharma, Inc.; Industry
Eligibility: 22 Years and older
Enrollment: 400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2031
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Glaucoma
Interventions: Bimatoprost; Drug
Lead sponsor: Innovative Medical; Industry
Eligibility: 18 Years and older
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Glaucoma, Ocular Hypertension
Interventions: Bimatoprost 0.01% ophthalmic solution, Bimatoprost 0.015% formulation 1 ophthalmic solution, Bimatoprost 0.015% formulation 2 ophthalmic solution, Bimatoprost 0.02% ophthalmic solution, Bimatoprost 0.03% ophthalmic solution; Drug
Lead sponsor: Allergan; Industry
Eligibility: 18 Years and older
Enrollment: 249 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005
U.S. locations: 1
States / cities: Wenatchee, Washington

Conditions: Idiopathic Eyelash Hypotrichosis
Interventions: bimatoprost formulation A solution, bimatoprost solution 0.03 %, vehicle of bimatoprost formulation A solution, vehicle of bimatoprost solution 0.03 %; Drug
Lead sponsor: Allergan; Industry
Eligibility: 18 Years and older
Enrollment: 464 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 1
States / cities: Newport Beach, California

Conditions: Glaucoma, Ocular Hypertension
Interventions: Bimatoprost Ophthalmic; Drug
Lead sponsor: Laboratoires Thea; Industry
Eligibility: 18 Years and older
Enrollment: 684 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 56
States / cities: Chandler, Arizona • Glendale, Arizona • Phoenix, Arizona + 47 more

Conditions: Glaucoma, Open-Angle, Ocular Hypertension
Interventions: Test - Bimatoprost 0.01% Ophthalmic Solution, Reference - LUMIGAN® (Bimatoprost 0.01% Ophthalmic Solution); Drug
Lead sponsor: Amneal Pharmaceuticals, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 168 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022
U.S. locations: 9
States / cities: Newport Beach, California • Petaluma, California • New Smyrna Beach, Florida + 6 more

Conditions: Glaucoma, Ocular Hypertension
Interventions: latanoprost 0.005% ophthalmic solution, Travoprost 004% sterile ophthalmic solution, Bimatoprost .03% sterile ophthalmic solution; Drug
Lead sponsor: Pfizer's Upjohn has merged with Mylan to form Viatris Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 375 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002
U.S. locations: 40
States / cities: Bellflower, California • Inglewood, California • San Diego, California + 31 more

Conditions: Glaucoma, Open-Angle, Ocular Hypertension
Interventions: AGN-210669 ophthalmic solution, 0.1%, AGN-210669 ophthalmic solution, 0.075%, AGN-210669 ophthalmic solution, 0.05%, bimatoprost ophthalmic solution 0.03%; Drug
Lead sponsor: Allergan; Industry
Eligibility: 18 Years and older
Enrollment: 165 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 1
States / cities: Rochester, New York

Conditions: Eyebrow Hypotrichosis
Interventions: bimatoprost solution, Vehicle to bimatoprost solution; Drug
Lead sponsor: Allergan; Industry
Eligibility: 18 Years and older
Enrollment: 357 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Open-angle Glaucoma, Ocular Hypertension
Interventions: AGN-193408 SR, Lumigan, Sham Administration, Lumigan Vehicle; Drug · Other
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2029
U.S. locations: 42
States / cities: Sun City, Arizona • Glendale, California • Inglewood, California + 38 more

Conditions: Glaucoma, Open-Angle, Ocular Hypertension
Interventions: Bimatoprost SR, Sham Bimatoprost SR, Selective Laser Trabeculoplasty, Sham Selective Laser Trabeculoplasty; Drug · Procedure
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years and older
Enrollment: 240 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2023
U.S. locations: 51
States / cities: Dothan, Alabama • Glendale, Arizona • Phoenix, Arizona + 43 more

Conditions: Scars, Hypopigmented Scar, Hypopigmented Skin, Burn Scar, Scarring, Cicatrix, Hypertrophic, Cicatrix, Pigmentation Disorder, Burns Laser
Interventions: Bimatoprost, Saline; Drug
Lead sponsor: Medstar Health Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Conditions: Open-Angle Glaucoma, Ocular Hypertension
Interventions: bimatoprost 0.03%, latanoprost 0.005%, and travoprost 0.004%; Drug
Lead sponsor: Allergan; Industry
Eligibility: 18 Years and older
Enrollment: 1,099 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2009
U.S. locations: 1
States / cities: Murfreesboro, Tennessee

Conditions: Alopecia, Alopecia, Androgenetic, Baldness
Interventions: bimatoprost Formulation A, bimatoprost Formulation B, bimatoprost Formulation C; Drug
Lead sponsor: Allergan; Industry
Eligibility: 18 Years to 64 Years
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: Tempe, Arizona

Search by objective public record fields.

A Safety and Efficacy Study of Bimatoprost in Men With Androgenic Alopecia (AGA)

Biomarkers of Ocular Surface Damage in the Setting of Topical Ocular Hypotensive Medication Use

Safety and Efficacy Study of Bimatoprost in Patients With Glaucoma or Ocular Hypertension

A Randomized, Double-blind, Parallel-group, Two-arm, Multiple Dose, Multicenter, Bioequivalence Study With Clinical Endpoint in the Treatment of Subjects With Chronic Open-angle Glaucoma or Ocular Hypertension in Both Eyes

Topical Bimatoprost in the Treatment of Migraine

Safety and Efficacy of AGN-210669 Ophthalmic Solution Compared With Bimatoprost Ophthalmic Solution in Patients With Open-Angle Glaucoma or Ocular Hypertension

An Open-Label Extension Study to Evaluate the Safety of the ForSight VISION5 Product

Study of Bimatoprost Gel on Eyelash Growth

Diurnal Curves With Bimatoprost 0.03% Versus Travoprost 0.004%

A Study of the Safety and Efficacy of Bimatoprost Ophthalmic Solution in Paediatric Patients With Glaucoma

Evaluation of the Safety and Efficacy of the Bimatoprost Implant System Used in Combination With the SpyGlass IOL Compared to Timolol Ophthalmic Solution (Rhone)

A Multicenter Evaluation of Methods to Reduce Hyperemia Associated With Bimatoprost Therapy for Glaucoma or Ocular Hypertension

Safety and Efficacy Study of Different Formulations of Bimatoprost Once-Daily in Patients With Glaucoma or Ocular Hypertension

Bimatoprost in the Treatment of Eyelash Hypotrichosis

Efficacy and Safety Assessment of T4032 (Unpreserved Bimatoprost 0.01%) Versus Lumigan® 0.01% in Ocular Hypertensive or Glaucomatous Patients

Bioequivalence Study With Clinical Endpoint Comparing Bimatoprost Ophthalmic Solution 0.01% and LUMIGAN® in the Treatment of Chronic Open-Angle Glaucoma or Ocular Hypertension in Both Eyes.

Comparison of Latanoprost With Travoprost and Bimatoprost in Patients With Elevated IOP. A 12-weeks, Masked Evaluator, Phase IV Multi-center Study in the US

Safety and Efficacy of Three Formulations of AGN-210669 Ophthalmic Solution Compared With Bimatoprost Ophthalmic Solution

Bimatoprost for the Treatment of Eyebrow Hypotrichosis

AGN-193408 SR in the Treatment of Open-angle Glaucoma or Ocular Hypertension

Comparison of Bimatoprost Sustained Release (SR) to Selective Laser Trabeculoplasty (SLT) in Adults With Open-Angle Glaucoma or Ocular Hypertension

Treatment of Hypopigmented Scars With Bimatoprost

Safety and Efficacy Study of Bimatoprost, Latanoprost, and Travoprost in Patients With Elevated Intraocular Pressure (IOP) and Open-angle Glaucoma (OAG)

Safety and Pharmacokinetics Study of New Formulation of Bimatoprost in Patients With Alopecia